Analysis of Hepatotoxicity Associated With TKIs in Solid Tumors

Tanios S. Bekaii-Saab, MD, analyzes the common adverse events (AEs) associated with tyrosine kinase inhibitors (TKIs) across solid tumors, with a special focus on hepatotoxicity and the clinical implications of this AE for future clinical studies of TKIs in combination with immune checkpoint inhibitors.

EP. 1: Overview of Toxicity Associated With TKIs in Solid Tumors

October 18th 2022

Tanios S. Bekaii-Saab, MD, describes the common adverse events associated with each type of tyrosine kinase inhibitor (TKI), which are specific to the targets hit by that TKI and commonly include fatigue and hepatotoxicity.

EP. 2: Understanding and Detecting TKI-Specific Hepatotoxicity

October 18th 2022

Tanios S. Bekaii-Saab, MD, describes the hepatotoxicity commonly seen with tyrosine kinase inhibitors (TKIs) and how to monitor and detect it with aspartate aminotransferase (AST) and alanine transaminase (ALT).

EP. 3: Vigilance Is Key in Mitigating TKI-Associated Hepatotoxicity

October 25th 2022

Liver injury can occur within 2 weeks of starting therapy with a tyrosine kinase inhibitor, although it can also be seen as late as 2 months, describes Tanios S. Bekaii-Saab, MD, making vigilance key for proper mitigation of this adverse event.

EP. 4: Reducing Adverse Events Through Dose Optimization

October 25th 2022

Tanios S. Bekaii-Saab, MD, discusses minimizing the toxicities associates with tyrosine kinase inhibitors (TKIs) through dose optimizations strategies, which are of particular interest at TKIs are combined with immune checkpoint inhibitors that also may impact the liver.

EP. 5: Novel Investigational Combination Strategies

November 1st 2022

Tanios S. Bekaii-Saab, MD, provides insight into ongoing research exploring novel combinations of tyrosine kinase inhibitors and immune checkpoint inhibitors across solid tumors.

EP. 6: Future Directions: Optimizing Care Through Combinations

November 1st 2022

Tanios S. Bekaii-Saab, MD, describes the future direct of clinical research into immune check point inhibitors for solid tumors, which he believes will be to explore additional combinations with targeted therapies.